Mutated K-rasAsp12 promotes tumourigenesis in ApcMin mice more in the large than the small intestines, with synergistic effects between K-ras and Wnt pathways

被引:55
作者
Luo, Feijun [1 ]
Brooks, David G. [1 ]
Ye, Hongtao [1 ]
Hamoudi, Rifat [1 ]
Poulogiannis, George [1 ]
Patek, Charles E. [2 ]
Winton, Douglas J. [3 ]
Arends, Mark J. [1 ]
机构
[1] Univ Cambridge, Addenbrookes Hosp, Dept Pathol, Cambridge CB2 2QQ, England
[2] Univ Edinburgh, Western Gen Hosp, Sir Alastair Currie Canc Res UK Labs, Mol Med Ctr, Edinburgh, Midlothian, Scotland
[3] Univ Cambridge, Dept Oncol, CRUK Cambridge Res Inst, Cambridge CB2 2QQ, England
关键词
adenoma; adenomatous polyposis coli; Cre; LoxP; intestine; K-ras; Min; ENDOTHELIAL GROWTH-FACTOR; ABERRANT CRYPT FOCI; GENE-EXPRESSION; BETA-CATENIN; COLORECTAL-CANCER; DETAILED ANALYSIS; ACTIVATOR TIAM1; ONCOGENIC RAS; MOUSE MODELS; COLON-CANCER;
D O I
10.1111/j.1365-2613.2009.00667.x
中图分类号
R36 [病理学];
学科分类号
100104 ;
摘要
P>K-ras mutations are found in 40-50% of human colorectal adenomas and carcinomas, but their functional contribution remains incompletely understood. Here, we show that a conditional mutant K-ras mouse model (K-rasAsp12/Cre), with transient intestinal Cre activation by beta-Naphthoflavone (beta-NF) treatment, displayed transgene recombination and K-rasAsp12 expression in the murine intestines, but developed few intestinal adenomas over 2 years. However, when crossed with ApcMin/+ mice, the K-rasAsp12/Cre/ApcMin/+ offspring showed acceleration of intestinal tumourigenesis with significantly changed average lifespan (P < 0.05) decreased to 18.4 +/- 5.4 weeks from 20.9 +/- 4.7 weeks (control ApcMin/+ mice). The numbers of adenomas in the small intestine and large intestine were significantly (P < 0.01) increased by 1.5-fold and 5.7-fold, respectively, in K-rasAsp12/Cre/ApcMin/+ mice compared with ApcMin/+ mice, with the more marked increase in adenoma prevalence in the large intestine. To explore possible mechanisms for K-rasAsp12 and ApcMin co-operation, the Mitogen-activated protein kinase (Mapk), Akt and Wnt signalling pathways, including selected target gene expression levels, were evaluated in normal large intestine and large intestinal tumours. K-rasAsp12 increased activation of Mapk and Akt signalling pathway targets phospho-extracellular signal-regulated kinase (pErk) and pAkt, and increased relative expression levels of Wnt pathway targets vascular endothelial growth factor (VEGF), gastrin, cyclo-oxygenase 2 (Cox2) and T-cell lymphoma invasion and metastasis 1 (Tiam1) in K-rasAsp12/Cre/ApcMin/+ adenomas compared with that of ApcMin/+ adenomas, although other Wnt signalling pathway target genes such as Peroxisome proliferator-activated receptor delta (PPARd), matrix metalloproteinase 7 (MMP7), protein phosphatase 1 alpha (PP1A) and c-myc remained unchanged. In conclusion, intestinal expression of K-rasAsp12 promotes mutant Apc-initiated intestinal adenoma formation in vivo more in the large intestine than the small intestine, with evidence of synergistic co-operation between mutant K-ras and Apc involving increased expression of some Wnt-pathway target genes.
引用
收藏
页码:558 / 574
页数:17
相关论文
共 60 条
[1]   Epithelial-cadherin and β-catenin expression changes in pancreatic intraepithelial neoplasia [J].
Al-Aynati, MM ;
Radulovich, N ;
Riddell, RH ;
Tsao, MS .
CLINICAL CANCER RESEARCH, 2004, 10 (04) :1235-1240
[2]   Kirsten ras mutations in patients with colorectal cancer:: the 'RASCAL II' study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, J ;
Dix, BR ;
Iacopetta, BJ ;
Young, J ;
Walsh, T ;
Ward, R ;
Hawkins, N ;
Beranek, M ;
Jandik, P ;
Benamouzig, R ;
Jullian, E ;
Laurent-Puig, P ;
Olschwang, S ;
Muller, O ;
Hoffmann, I ;
Rabes, HM ;
Zietz, C ;
Troungos, C ;
Valavanis, C ;
Yuen, ST ;
Ho, JWC ;
Croke, CT ;
O'Donoghue, DP ;
Giaretti, W ;
Rapallo, A ;
Russo, A ;
Bazan, V ;
Tanaka, M ;
Omura, K ;
Azuma, T ;
Ohkusa, T ;
Fujimori, T ;
Ono, Y ;
Pauly, M ;
Faber, C ;
Glaesener, R ;
de Goeij, AFPM ;
Arends, JW ;
Andersen, SN ;
Lövig, T ;
Breivik, J ;
Gaudernack, G ;
Clausen, OPF ;
De Angelis, P ;
Meling, GI ;
Rognum, TO ;
Smith, R .
BRITISH JOURNAL OF CANCER, 2001, 85 (05) :692-696
[3]   Kirsten ras mutations in patients with colorectal cancer: the multicenter "RASCAL" study [J].
Andreyev, HJN ;
Norman, AR ;
Cunningham, D ;
Oates, JR ;
Clarke, PA .
JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (09) :675-684
[4]  
Araki Y, 2003, CANCER RES, V63, P728
[5]  
ARENDS MJ, 1994, AM J PATHOL, V144, P1045
[6]   SUSCEPTIBILITY TO APOPTOSIS IS DIFFERENTIALLY REGULATED BY C-MYC AND MUTATED HA-RAS ONCOGENES AND IS ASSOCIATED WITH ENDONUCLEASE AVAILABILITY [J].
ARENDS, MJ ;
MCGREGOR, AH ;
TOFT, NJ ;
BROWN, EJH ;
WYLLIE, AH .
BRITISH JOURNAL OF CANCER, 1993, 68 (06) :1127-1133
[7]  
ARENDS MJ, 2005, EFFECTIVE MANAGEMENT, P25
[8]   Use of retrovirus expression of interfering RNA to determine the contribution of activated K-ras and ras effector expression to human tumor cell growth [J].
Baines, Antonio T. ;
Lim, Kian-Huat ;
Shields, Janiel M. ;
Lambert, John M. ;
Counter, Christopher M. ;
Der, Channing J. ;
Cox, Adrienne D. .
REGULATORS AND EFFECTORS OF SMALL GTPASES: RAS FAMILY, 2006, 407 :556-+
[9]   RAS GENES [J].
BARBACID, M .
ANNUAL REVIEW OF BIOCHEMISTRY, 1987, 56 :779-827
[10]   PREVALENCE OF RAS GENE-MUTATIONS IN HUMAN COLORECTAL CANCERS [J].
BOS, JL ;
FEARON, ER ;
HAMILTON, SR ;
VERLAANDEVRIES, M ;
VANBOOM, JH ;
VANDEREB, AJ ;
VOGELSTEIN, B .
NATURE, 1987, 327 (6120) :293-297